Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Basit Öğe Kaydı
dc.authoridAlvares-da-Silva, Mario Reis/0000-0002-5001-246X
dc.authoridHatemi, Ali Ibrahim/0000-0002-8385-9253
dc.authoridDrenth, Joost/0000-0001-8027-3073
dc.authoridEbik, Berat/0000-0002-0012-2505
dc.authoriddhanasekaran, renumathy/0000-0001-8819-7511
dc.authoridEŞKAZAN, TUĞÇE/0000-0003-3008-1940
dc.authoridGüzelbulut, Fatih/0000-0003-4889-208X
dc.authorwosidAlvares-da-Silva, Mario Reis/L-3910-2014
dc.authorwosidHatemi, Ali Ibrahim/AAA-3618-2020
dc.authorwosidDrenth, Joost/V-7436-2019
dc.authorwosidEbik, Berat/AAM-5646-2020
dc.authorwosiddhanasekaran, renumathy/B-3300-2014
dc.authorwosidEŞKAZAN, TUĞÇE/ABA-8299-2020
dc.authorwosidGüzelbulut, Fatih/AAF-9450-2019
dc.contributor.authorEfe, Cumali
dc.contributor.authorLammert, Craig
dc.contributor.authorTascilar, Koray
dc.contributor.authorDhanasekaran, Renumathy
dc.contributor.authorEbik, Berat
dc.contributor.authorHiguera-de la Tijera, Fatima
dc.contributor.authorCaliskan, Ali R.
dc.date.accessioned2024-08-04T20:50:55Z
dc.date.available2024-08-04T20:50:55Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH.en_US
dc.description.sponsorshipItalian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic)en_US
dc.description.sponsorshipA. Gerussi, L. Cristoferi, and P. Invernizzi acknowledge that this research was partially supported by the Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic).en_US
dc.identifier.doi10.1111/liv.15121
dc.identifier.endpage614en_US
dc.identifier.issn1478-3223
dc.identifier.issn1478-3231
dc.identifier.issue3en_US
dc.identifier.pmid34846800en_US
dc.identifier.scopus2-s2.0-85121047570en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage607en_US
dc.identifier.urihttps://doi.org/10.1111/liv.15121
dc.identifier.urihttps://hdl.handle.net/11616/100362
dc.identifier.volume42en_US
dc.identifier.wosWOS:000729531700001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofLiver Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectautoimmunityen_US
dc.subjectazathioprineen_US
dc.subjectbudesonideen_US
dc.subjectliver transplantationen_US
dc.subjectmercaptopurineen_US
dc.subjectSARS-CoV-2en_US
dc.titleEffects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu